The European Commission recently launched a targeted stakeholder consultation on draft Guidelines on Good Manufacturing Practice for Advanced Therapy Medicinal Products, pursuant to Article 5 of Regulation 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC, that requires the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products. EIPG has reviewed the documents and. following feedback from its members, has submitted its comments to the Commission.
-
-
News from EIPG
- Environmental sustainability: the EIPG perspective
- How AI is Changing the Pharma Industry and the Industrial Pharmacist’s Role
- Generative AI in drug development
- PGEU annual medicine shortages report
- EMA’s pilot scheme for academic and non-profit development of ATMPs
- Lessons learnt to transition from Horizon 2020 to the new FP10
- Approvals and flops in drug development in 2023